Charles Schwab
AGTC

Charles Schwab’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Charles Schwab’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,820
Closed -$25K – 3648
2021
Q4 		$25K Hold
12,820
– – ﹤0.01% 3574
2021
Q3 		$39K Hold
12,820
– – ﹤0.01% 3474
2021
Q2 		$51K Sell
12,820
-91,310
-88% -$379K ﹤0.01% 3367
2021
Q1 		$528K Buy
104,130
+35,648
+52% +$185K ﹤0.01% 3063
2020
Q4 		$281K Buy
68,482
+5,353
+8% +$26.3K ﹤0.01% 3183
2020
Q3 		$307K Hold
63,129
– – ﹤0.01% 3023
2020
Q2 		$350K Buy
+63,129
New +$289K ﹤0.01% 2975
2017
Q2 		– Sell
-17,400
Closed -$121K – 3158
2017
Q1 		$121K Hold
17,400
– – ﹤0.01% 2996
2016
Q4 		$163K Hold
17,400
– – ﹤0.01% 2996
2016
Q3 		$171K Hold
17,400
– – ﹤0.01% 2947
2016
Q2 		$246K Hold
17,400
– – ﹤0.01% 2862
2016
Q1 		$244K Hold
17,400
– – ﹤0.01% 2835
2015
Q4 		$355K Buy
+17,400
New +$268K ﹤0.01% 2796

Other funds holding AGTC

CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Charles Schwab's AGTC Position: Q1 2022 in Review

Charles Schwab sold out of Applied Genetic Technologies Corporation (AGTC) in Q1 2022, closing a stake of 12,820 shares — an estimated $25K sold.

Charles Schwab first reported a position in AGTC in Q4 2015 and held it in 13 quarters. The position peaked at $528K in Q1 2021. 53 funds tracked by Wall St. Rank hold AGTC as of Q1 2022.

  • Charles Schwab reported no remaining Applied Genetic Technologies Corporation position as of Q1 2022 after selling out during the quarter.
  • Charles Schwab sold 12,820 Applied Genetic Technologies Corporation shares in Q1 2022, an estimated $25K.
  • Charles Schwab first reported a position in Applied Genetic Technologies Corporation in Q4 2015 and held it in 13 quarters.
  • Charles Schwab's Applied Genetic Technologies Corporation position peaked at $528K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q1 2022.

Based on Charles Schwab's 13F filing for Q1 2022, filed 13 May 2022.